# BGT007H Cells for the Treatment of Recurrent/Refractory Gastrointestinal Tumors

> **NCT06152757** · EARLY_PHASE1 · RECRUITING · sponsor: **BioSyngen Pte Ltd** · enrollment: 14 (estimated)

## Conditions studied

- Gastrointestinal Tumors

## Interventions

- **BIOLOGICAL:** First dose
- **BIOLOGICAL:** Second dose
- **BIOLOGICAL:** The third dose
- **BIOLOGICAL:** The fourth dose

## Key facts

- **NCT ID:** NCT06152757
- **Lead sponsor:** BioSyngen Pte Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-09
- **Primary completion:** 2025-07-19
- **Final completion:** 2027-07-19
- **Target enrollment:** 14 (ESTIMATED)
- **Last updated:** 2023-12-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06152757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06152757, "BGT007H Cells for the Treatment of Recurrent/Refractory Gastrointestinal Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06152757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*